India unlikely to resume COVID jab exports until October: Report

India is unlikely to resume major exports of COVID-19 vaccines until at least October, government sources say.

India is unlikely to resume major exports of COVID-19 vaccines until at least October as it diverts shots for domestic use, three government sources said, a longer-than-expected delay set to worsen supply shortages from the global COVAX initiative. The Serum Institute of India (SII), the world’s biggest vaccine maker producing the AstraZeneca vaccine, responded by saying that it hoped to restart deliveries to COVAX and other countries by the end of this year. “We would like to reiterate that we have never exported vaccines at the cost of the people of India and remain committed to do everything we can in the support of the vaccination drive in the country,” SII said in a statement on Tuesday.